Abstract
Stryker will report fiscal first-quarter 2026 results on April 30, 2026 Post Market, with investor attention centered on whether revenue growth near low double digits and margin execution can sustain momentum amid procedure volumes and capital spending trends.Market Forecast
Consensus points to continued expansion for the current quarter: revenue is forecast at 6.34 billion US dollars, implying 11.11% year-over-year growth; EBIT is projected at 1.46 billion US dollars with 13.64% year-over-year growth; and adjusted EPS is estimated at 2.99, up 10.58% year-over-year. Company-level metrics tracked by the market suggest continued healthy margin structure; the prior quarter’s reported gross margin of 65.22% and net profit margin of 11.84% frame expectations for stable-to-improving profitability. Main business dynamics are expected to reflect resilient procedure volumes and steady pricing, with Orthopedics demand supported by backlog normalization and Surgical and Neurotechnology benefiting from installed base utilization. The most promising segment is Surgical and Neurotechnology, with last quarter revenue of 4.56 billion US dollars and a strong trajectory supported by operating room integration, endoscopy, and power tools exposure.Last Quarter Review
Stryker’s previous quarter delivered revenue of 7.17 billion US dollars, a gross margin of 65.22%, GAAP net profit attributable to shareholders of 0.85 billion US dollars, a net profit margin of 11.84%, and adjusted EPS of 4.47, with year-over-year growth in revenue and adjusted EPS of 11.42% and 11.47%, respectively. One notable highlight was sustained double-digit top-line growth alongside EBIT outperformance versus market expectations, supporting operating leverage even as investments continued across innovation and commercial capacity. The company’s main businesses reflected balanced growth, with Surgical and Neurotechnology contributing 4.56 billion US dollars and Orthopedics contributing 2.60 billion US dollars, reinforcing a diversified revenue base.Current Quarter Outlook
Main business: Orthopedics and Surgical and Neurotechnology
Orthopedics is positioned to benefit from solid elective procedure volumes and backlog normalization, which should support reconstructive implants and trauma growth. Replacement cycles for premium hip and knee systems, along with incremental gains from enabling technologies, could help lift mix and sustain pricing. Inventory normalization across distributors and hospitals should temper volatility, while cross-selling with navigation and robotics can add to ASP resilience.Surgical and Neurotechnology remains a growth engine given operating room integration demand, endoscopy portfolio strength, and continued adoption in power tools and advanced visualization. Hospital capital budgets appear selective but supportive of equipment tied to efficiency and throughput, which fits well with Stryker’s portfolio leverage. Higher utilization levels may also favor recurring revenue streams and service, underpinning steady top-line contributions. Strong attachment rates with disposables and software are tailwinds for gross margin durability.
Across both franchises, integration of enabling technologies and connectivity continues to enhance procedural efficiency and data capture, helping sustain premium positioning. These dynamics can translate into incremental operating margin leverage if volume growth remains in the low double digits and pricing/mix stays firm. The near-term sensitivity remains on the cadence of hospital spending and procedure intensity across geographies.
Most promising business: Surgical and Neurotechnology
Surgical and Neurotechnology’s scale, product breadth, and recurring revenue mix make it the most promising near-term driver. The prior quarter’s 4.56 billion US dollars contribution highlights the segment’s weight and momentum into 2026. Demand for operating room integration, visualization platforms, and power tools is closely tied to hospitals’ push for efficiency, which has persisted as procedure volumes normalize and staffing constraints require productivity solutions.Cross-portfolio synergies—pairing towers, endoscopy, and OR integration—should support share gains and multi-year upgrade cycles. Software and services layers deepen customer stickiness and add high-margin revenue streams, providing a buffer against capital-spending variability. If the capital environment stays constructive, the segment can outgrow the company average; if it tightens, the installed base and consumables tilt can maintain solid performance.
From a profitability perspective, the favorable mix in Surgical and Neurotechnology supports gross margin consistency. With scale benefits and moderated supply chain pressures, conversion of revenue growth into EBIT expansion appears achievable, aligning with the 13.64% year-over-year increase embedded in current-quarter EBIT expectations.
Key stock price swing factors this quarter
The first variable is revenue conversion versus procedure volumes—low double-digit top-line growth is expected, so any deviation due to case mix, seasonality, or regional slowdowns could drive outsized moves. The second is margin quality—investors will scrutinize gross margin trend relative to the prior quarter’s 65.22% and the flow-through to EBIT and EPS, particularly in light of cost normalization and pricing discipline. The third is capital equipment demand—hospitals’ appetite for OR integration and endoscopy upgrades can influence the trajectory within Surgical and Neurotechnology and signal the durability of growth into the second half of 2026.Order book commentary and qualitative color on pipeline strength will also inform expectations for the remainder of the fiscal year. Any updates on innovation cadence in robotics, navigation, or data/analytics could shift medium-term growth assumptions and valuation multiples. Currency and emerging-market dynamics are secondary but worth monitoring if they materially affect reported growth or margins.
Analyst Opinions
The prevailing view among analysts tilts bullish, focusing on continued revenue growth in the low double digits and constructive margin progression supported by mix and operating leverage. A commonly cited upside case emphasizes procedure normalization and sustained equipment demand in Surgical and Neurotechnology, projecting adjusted EPS near 2.99 with room for modest beat if gross margin holds at or above the recent 65.22% level. Institutions highlighting this view argue that balanced growth across Orthopedics and Surgical and Neurotechnology reduces reliance on any single sub-vertical and supports stable free cash generation.Several well-known sell-side teams emphasize that EBIT growth guided by the market at 13.64% year over year appears well aligned with easing supply chain costs and favorable pricing. These analysts underscore that the company’s diversified hospital-facing portfolio and recurring revenue attachments serve as resilience factors even if capital cycles soften. They also note that valuation sensitivity will hinge on the quality of beat-and-raise potential; clean gross margin progression alongside in-line revenue could sustain multiple support.
A minority more cautious stance focuses on the possibility of uneven hospital capital spending and seasonal variability in case volumes. However, the bullish camp remains the majority in recent commentary, pointing to strong prior-quarter execution, modest upside risk to EPS, and a durable growth algorithm near the low double-digit range. Overall, the consensus skew is constructive heading into April 30, 2026 Post Market, with investors looking for confirmation that top-line momentum and profit conversion remain on track.
Comments